Roche's lung cancer drug wins US approval
Swiss drugmaker Roche Holding AG's new immunotherapy, Tecentriq, won approval on Tuesday from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb's position in this hotly contested market.
The U.S. Food and Drug Administration approved Tecentriq to be used in non-small cell lung cancer patients previously treated with chemotherapy, regardless of whether their tumors express a protein called PD-L1. People with high PD-L1 levels are generally more receptive to immunotherapy.
In study results released this month, patients getting... read more
- 04:22 Russia: Asking permission before taking organs is 'inhumane'
- 02:28 Brewers' broadcaster Bob Uecker survives venomous spider bite,...
- 00:30 Allegations from women in his past shadow Trump
- 00:30 GOP senators criticize Trump for congratulating Putin on win
- 00:30 Tariffs on steel, aluminum set off scramble for exemptions
- 23:27 Hamilton baseball walks off to complete rally over Desert Vista
- 23:18 Detroit Red Wings stop losing skid, top Philadelphia Flyers 5-4 in SO
- 21:35 Brazil to vaccinate entire country against yellow fever
- 20:45 Lupe Valdez touts Dan Patrick in fundraising for Dem gubernatorial...
- 20:45 Trump warns of dire consequences if Democrats take House